China Biologic Products (CBPO) Reports Q1 EPS of $0.94
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
China Biologic Reports Financial Results for the First Quarter of 2016
May 4, 2016 5:00 PM EDTBEIJING, May 4, 2016 /PRNewswire/ --Â China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the first quarter of 2016.
First Quarter 2016 Financial Highlights
Total sales in the first quarter of 2016 increased by 29.4% in RMB terms, or 21.6% in USD terms, to $85.6 million from $70.4 million in the same quarter of 2015. Gross profit increased by 12.2% to $51.5 million from $45.9 million in the same quarter of 2015. Gross margin decreased to 60.2% in the... More